Patents by Inventor Martin G. Pomper

Martin G. Pomper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY
    Publication number: 20240150323
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: October 3, 2023
    Publication date: May 9, 2024
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY
    Publication number: 20240140971
    Abstract: PSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.
    Type: Application
    Filed: June 14, 2023
    Publication date: May 2, 2024
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray, Michael Zalutsky, Ganesan Vaidyanathan
  • DEVELOPMENT OF NEW MONOCLONAL ANTIBODIES RECOGNIZING HUMAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
    Publication number: 20240101706
    Abstract: The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and therapy of PSMA-expressing cancers, such as prostate cancer, in a subject.
    Type: Application
    Filed: September 29, 2023
    Publication date: March 28, 2024
    Inventors: Cyril Barinka, Martin G. Pomper, Zora Novakova, Catherine A. Foss
  • Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha)
    Patent number: 11938201
    Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: March 26, 2024
    Assignee: The Johns Hopkins University
    Inventors: Xing Yang, Sridhar Nimmagadda, Steven Rowe, Stephanie Slania, Martin G. Pomper
  • Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
    Patent number: 11911488
    Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: February 27, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSTY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray, Ying Chen, Xing Yang
  • PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED PRODRUG FOR SELECTIVE KILLING OF CELLS EXPRESSING PSMA
    Publication number: 20230414762
    Abstract: A non-radioactive prodrug comprising a PSMA-targeted moiety, a cleavable linker, and an antineoplastic agent capable of selectively killing PSMA-expressing cells and methods of treating a disease or condition associated with PSMA-expressing tumors or cells is disclosed.
    Type: Application
    Filed: November 17, 2021
    Publication date: December 28, 2023
    Inventors: Srikanth Boinapally, IL Minn, Martin G. Pomper
  • Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [F]DCFPYL
    Patent number: 11851407
    Abstract: Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: December 26, 2023
    Assignee: THE JOHNS HOPKINS UNIVERSTY
    Inventors: Hayden T. Ravert, Daniel P. Holt, Ying Chen, Ronnie C. Mease, Hong Fan, Martin G. Pomper, Robert F. Dannals
  • IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)
    Publication number: 20230364274
    Abstract: Imaging and radiotherapeutics agents targeting fibroblast-activation protein-? (FAP-?) and their use in imaging and treating FAP-? related diseases and disorders are disclosed.
    Type: Application
    Filed: July 18, 2023
    Publication date: November 16, 2023
    Inventors: Xing Yang, Sridhar Nimmagadda, Steven Rowe, Stephanie Slania, Martin G. Pomper
  • PSMA targeted fluorescent agents for image guided surgery
    Patent number: 11814365
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 14, 2023
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
    Patent number: 11813340
    Abstract: Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: November 14, 2023
    Assignees: The Johns Hopkins University, Duke University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Vivek Kumar, Sangeeta Ray, Michael Zalutsky, Ganesan Vaidyanathan
  • PSMA-TARGETING COMPOUNDS AND USES THEREOF
    Publication number: 20230348405
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: November 4, 2022
    Publication date: November 2, 2023
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
    Patent number: 11773182
    Abstract: The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and therapy of PSMA-expressing cancers, such as prostate cancer, in a subject.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 3, 2023
    Assignees: The Johns Hopkins University, Institute of Biotechnology CAS, V.V.I.
    Inventors: Cyril Barinka, Martin G. Pomper, Zora Novakova, Catherine A. Foss
  • Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy
    Patent number: 11697804
    Abstract: A DNA plasmid useful for diagnostic and therapeutic gene therapy is disclosed. Improvements to gene therapy methods known in the art are provided to ensure cancer-targeting, high efficacy, and long durability of expression. The DNA plasmid is combined with compositions of polymeric nanoparticles for non-viral gene therapy to treat cancer, including hepatocellular carcinoma and prostate cancer.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: July 11, 2023
    Assignee: The Johns Hopkins University
    Inventors: Jordan J. Green, Martin G. Pomper, Camila Gadens Zamboni, Hannah Vaughan, Il Minn
  • ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS
    Publication number: 20230190796
    Abstract: Provided are cells, such as engineered cells, that express a prostate-specific membrane antigen (PSMA) or a modified form thereof. In some embodiments, the cell further contains a genetically engineered recombinant receptor, such as a chimeric antigen receptor, that specifically binds to an antigen. The present disclosure also provides methods of detecting, identifying, selecting or targeting cells expressing PSMA, such as in connection with administration of such cells to subjects, including methods of adoptive cell therapy, or in connection with methods of manufacturing engineered cells.
    Type: Application
    Filed: April 7, 2018
    Publication date: June 22, 2023
    Applicants: Juno Therapeutics, Inc., The Johns Hopkins University
    Inventors: David Jeffrey HUSS, Hyam I. LEVITSKY, Il MINN, Martin G. POMPER
  • PSMA-targeting compounds and uses thereof
    Patent number: 11661402
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: May 30, 2023
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
    Publication number: 20230147035
    Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
    Type: Application
    Filed: October 24, 2022
    Publication date: May 11, 2023
    Inventors: Sangeeta Ray, Martin G. Pomper
  • PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
    Publication number: 20230015736
    Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
    Type: Application
    Filed: August 22, 2022
    Publication date: January 19, 2023
    Inventors: SANGEETA RAY, MARTIN G. POMPER
  • LOW MOLECULAR WEIGHT AND POLYAMIDOAMINE (PAMAM) DENDRIMER BASED PSMA-SPECIFIC DUAL CONTRAST AGENTS FOR OPTICAL AND PHOTOACOUSTIC IMAGING AND THERANOSTIC AGENTS FOR TREATING PROSTATE CANCER
    Publication number: 20220401592
    Abstract: Poly(amidoamine) [PAMAM] dendrimers for use as PSMA-targeted contrast agents for optical and photoacoustic imaging (PA) and theranostic agents for treating prostate cancer are disclosed.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 22, 2022
    Inventors: Martin G. Pomper, Wojciech Lesniak, Emad Boctor, Sangeeta Banerjee Ray, Srikanth Boinapally, Jeeun Kang, Yixuan Wu
  • Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
    Patent number: 11478558
    Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: October 25, 2022
    Assignee: The Johns Hopkins University
    Inventors: Sangeeta Ray, Martin G. Pomper
  • Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
    Patent number: 11458213
    Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: October 4, 2022
    Inventors: Sangeeta Ray, Martin G. Pomper